LXRX
Lexicon Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -22.2% ·
share flow +30.0% ·
net new positions -20.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +16 | 115.42M | $276.97M | +20 | −4 |
| Q1 2026 | 53 | +1 | 96.42M | $150.42M | +5 | −4 |
| Q4 2025 | 51 | +1 | 73.64M | $84.69M | +2 | −1 |
| Q3 2025 | 13 | 0 | 62.78M | $84.76M | +2 | −2 |
| Q2 2025 | 10 | +2 | 57.50M | $54.38M | +4 | −2 |
| Q1 2025 | 5 | -2 | 7.56M | $3.49M | +1 | −3 |
| Q4 2024 | 7 | -2 | 16.13M | $11.91M | +1 | −3 |
| Q3 2024 | 8 | 0 | 7.88M | $12.37M | — | — |
| Q2 2024 | 8 | — | 12.44M | $20.91M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 8.99M | +630.7% | $6.64M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 3.52M | -0.1% | $2.60M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 3.52M | -0.1% | $2.60M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 2.72M | — | $2.01M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 748.00K | +2.1% | $552,395 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 748.00K | +2.1% | $552,395 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 77.50K | -33.9% | $57,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 51.14K | New | $37,768 | 0.0% | New | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 25.83K | -73.8% | $19,077 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $37,768 | 0.0% |
Exited
| Millennium Management | $2.20M | was 0.0% |
| Marshall Wace | $901,416 | was 0.0% |
| Two Sigma Investments | $321,660 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 136 holders, 323.38M shares, $502.11M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.